...
首页> 外文期刊>JAMA: the Journal of the American Medical Association >Management of recalled pacemakers and implantable cardioverter-defibrillators: a decision analysis model.
【24h】

Management of recalled pacemakers and implantable cardioverter-defibrillators: a decision analysis model.

机译:召回的起搏器和植入式心脏复律除颤器的管理:决策分析模型。

获取原文
获取原文并翻译 | 示例
           

摘要

CONTEXT: Limited information exists to direct clinical management after an implantable device has been put under advisory. A better understanding of the risks and benefits of device replacement compared with continued clinical follow-up would be helpful to clinicians. OBJECTIVE: Using the tools of decision analysis, to determine the best management approach (immediate device replacement vs continued monitoring) in the setting of a device advisory. DESIGN: A decision model was constructed to evaluate the risks and benefits associated with immediate device replacement compared with continued monitoring. MAIN OUTCOME MEASURES: Variables considered included indications for device implantation, anticipated course following device failure, device failure rates from the advisory ranging from 0.0001% to 1.0% per year, and device replacement mortality rates ranging from 0.10% to 1.00% per procedure. Device replacement was preferred to continued follow-up when replacement led to greater patient survival. RESULTS: The decision to replace a recalled device depends primarily on the advisory's estimated device failure rate and the likely effects of device failure on mortality. Procedural mortality is an important secondary factor, while patient age and remaining generator life have the least influence on the decision. For pacemaker-dependent patients, advisory device failure rates exceeding 0.3% warrant device replacement in most situations. In patients with implantable cardioverter-defibrillators for primary or secondary prevention, a failure rate associated with an advisory of 3.0% is needed to favor replacement in most cases, decreasing to close to 1.0% as procedural mortality rates decrease to 0.1% or risk of fatal arrhythmias increase to near 20% per year. In cases of pacemaker implantation for non-life-threatening situations (eg, carotid sinus hypersensitivity), most device advisories do not warrant device replacement. CONCLUSIONS: The decision to replace a device under advisory is determined primarily by the incidence of device malfunction and the likely effects of device failure. This analysis provides a framework for managing recalled devices in the context of device, patient, and institutional characteristics.
机译:背景:在将植入式设备置于咨询之下后,用于指导临床管理的信息有限。与持续的临床随访相比,更好地了解器械更换的风险和益处将对临床医生有所帮助。目的:使用决策分析工具来确定设置设备咨询时的最佳管理方法(立即更换设备还是持续监控)。设计:建立了决策模型,以评估与持续监控相比,立即更换设备所带来的风险和收益。主要观察指标:所考虑的变量包括设备植入的适应症,设备故障后的预期病程,咨询中的设备故障率每年为0.0001%至1.0%,以及每次手术过程中设备更换的死亡率为0.10%至1.00%。当替换可导致更大的患者生存率时,首选设备替换而非继续随访。结果:更换召回设备的决定主要取决于咨询机构的估计设备故障率以及设备故障对死亡率的可能影响。手术死亡率是重要的次要因素,而患者年龄和发电机剩余寿命对决定的影响最小。对于依赖起搏器的患者,在大多数情况下,咨询设备的故障率超过0.3%即可更换设备。在具有用于一级或二级预防的植入式心脏复律除颤器的患者中,建议3.0%的咨询失败率来支持置换,在大多数情况下,由于手术死亡率降低至0.1%或有致命危险,降低至接近1.0%心律失常每年增加近20%。对于非生命危险的情况(例如,颈动脉窦超敏反应)植入起搏器的情况,大多数设备咨询均不保证需要更换设备。结论:根据咨询意见更换设备的决定主要取决于设备故障的发生率和设备故障的可能影响。该分析提供了在设备,患者和机构特征的上下文中管理召回设备的框架。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号